… Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment
of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. …

… The primary aim of this study was to assess the relative dose intensity of cetuximab in
patients with R/M SCCHN treated with first-line cetuximab according to the EXTREME regimen. …

… in head and neck squamous cell carcinoma (HNSCC) patients, but the emergence of cetuximab
… R521K alteration on efficiency of cetuximab therapy of HNSCC cell lines and tried to find …

… of cetuximab and cisplatin alone or in combination with paclitaxel as the first-line
treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). …

… Advantages of biweekly versus weekly administration of cetuximab for patients with
metastatic colorectal cancer (mCRC), and squamous cell carcinoma of the head and neck (SCCHN) …

… There were 10 grade 3 treatment-related toxicities in 29 pts, of which 3 (1 fatigue, 2
mucositis oral) had at least possible attribution to both study drugs, resulting in cetuximab …

… head/neck cancer patients with a conjugate of the anti‐epidermal growth factor receptor (EGFR)
antibody, Cetuximab … overexpressing human head/neck OSC‐19‐luc2‐cGFP tumor with …

… Most patients with HPV associated squamous cell carcinoma of the head and neck, treated
… with cetuximab. To improve local control and mitigate the negative impact of a large tumor …

… controlled trials (RCTs) to revaluate the efficacy and safety of cetuximab vs. cisplatin
combined with radiotherapy in patients of head and neck squamous cell carcinoma (HNSCC). …

… with cetuximab is an alternative for advanced-stage head and neck squamous cell carcinoma
… PD-L1 immune checkpoint blockade (avelumab) with cetuximab-RT in the curative setting. …